REGN Regeneron Pharmaceuticals Inc

Price (delayed)

$663.09

Market cap

$69.52B

P/E Ratio

15.58

Dividend/share

$3.64

EPS

$42.56

Enterprise value

$69.26B

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 83

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Tarrytown, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities , it ...

Highlights
REGN's price to earnings (P/E) is 9% lower than its 5-year quarterly average of 17.1
The equity has grown by 7% year-on-year
The quick ratio has contracted by 27% YoY and by 13% from the previous quarter

Key stats

What are the main financial stats of REGN

REGN stock price

How has the Regeneron Pharmaceuticals stock price performed over time
Intraday
-0.22%
1 week
2.04%
1 month
8.32%
1 year
16.79%
YTD
-14.09%
QTD
6.34%

Financial performance

How have Regeneron Pharmaceuticals's revenue and profit performed over time
Revenue
$14.92B
Gross profit
$12.61B
Operating income
$3.63B
Net income
$4.42B
Gross margin
84.5%
Net margin
29.6%
Regeneron Pharmaceuticals's operating margin has decreased by 11% YoY and by 2.4% QoQ
The net margin has decreased by 7% YoY and by 6% from the previous quarter
The revenue has increased by 6% YoY and by 4% QoQ
The operating income fell by 5% YoY

Price vs fundamentals

How does REGN's price correlate with its fundamentals

Growth

What is Regeneron Pharmaceuticals's growth rate over time

Valuation

What is Regeneron Pharmaceuticals stock price valuation
P/E
15.58
P/B
2.23
P/S
4.62
EV/EBIT
13.31
EV/EBITDA
12.06
EV/Sales
4.64
REGN's price to earnings (P/E) is 9% lower than its 5-year quarterly average of 17.1
REGN's price to book (P/B) is 30% less than its 5-year quarterly average of 3.2 and 3% less than its last 4 quarters average of 2.3
The equity has grown by 7% year-on-year
The P/S is 20% lower than the 5-year quarterly average of 5.8
The revenue has increased by 6% YoY and by 4% QoQ

Efficiency

How efficient is Regeneron Pharmaceuticals business performance
The return on assets has declined by 8% year-on-year and by 3.5% since the previous quarter
Regeneron Pharmaceuticals's return on equity has decreased by 8% YoY and by 3.4% QoQ
The company's return on sales fell by 5% QoQ and by 2.2% YoY
Regeneron Pharmaceuticals's return on invested capital has decreased by 2.6% QoQ

Dividends

What is REGN's dividend history
DPS
$3.64
Dividend yield
0.55%
Payout ratio
8.6%
Recent dividends

Special dividends are included in TTM DPS and yield

Financial health

How did Regeneron Pharmaceuticals financials performed over time
The current ratio is down by 28% YoY and by 14% QoQ
The quick ratio has contracted by 27% YoY and by 13% from the previous quarter
The debt is 91% less than the equity
The equity has grown by 7% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.